Positive Q1 Trading Update

AI SummaryClose X

Verici Dx plc reported a strong first quarter for 2026, with Tutivia™ testing volumes increasing 32% quarter-on-quarter to 392 and 34% year-on-year, exceeding management expectations. Seven new transplant centres ordered tests, and one centre integrated Tutivia™ into its clinical protocols. Repeat ordering centres showed significant growth, with six increasing volumes by over 20%, and two of the largest centres seeing more than 30% growth. Tutivia™ is now approved in 17 US State Medicaid programmes, in addition to Medicare coverage. The company also appointed a new Senior Director of Sales to further drive momentum.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings